Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ehjci/jeaf169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aim: Hydrocephalus is a condition characterized by the excessive accumulation of cerebrospinal fluid in the brain's ventricular system, leading to ventricular enlargement and increased intracranial pressure. This study aimed to evaluate whether transfontanel ultrasonography could serve as a practical and less complex alternative to brain magnetic resonance imaging in infants with hydrocephalus.
Material And Methods: In this prospective study, 54 infants diagnosed with hydrocephalus underwent both transfontanel ultrasonography and brain magnetic resonance imaging.
Arterial Stiffness in HFpEF: From Clinical Insight to Bedside Action.
Cardiol Rev
September 2025
From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.
Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.
View Article and Find Full Text PDFEnhancing one-year mortality prediction in STEMI patients post-PCI: an interpretable machine learning model with risk stratification.
Front Artif Intell
August 2025
The First Clinical Medical School, Lanzhou University, Lanzhou, China.
Background: ST-elevation myocardial infarction (STEMI) poses a significant threat to global mortality and disability. Advances in percutaneous coronary intervention (PCI) have reduced in-hospital mortality, highlighting the importance of post-discharge management. Machine learning (ML) models have shown promise in predicting adverse clinical outcomes.
View Article and Find Full Text PDFValue and validation of a nomogram model based on the Charlson comorbidity index for predicting in-hospital mortality in patients with acute myocardial infarction complicated by ventricular arrhythmias.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Cardiovascular Medicine, Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha 410005.
Objectives: The Charlson comorbidity index reflects overall comorbidity burden and has been applied in cardiovascular medicine. However, its role in predicting in-hospital mortality in patients with acute myocardial infarction (AMI) complicated by ventricular arrhythmias (VA) remains unclear. This study aims to evaluate the predictive value of the Charlson comorbidity index in this setting and to construct a nomogram model for early risk identification and individualized management to improve outcomes.
View Article and Find Full Text PDFSacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.
Eur J Heart Fail
September 2025
Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
Aims: The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.
Methods And Results: PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%.